SEC EDGARNOV 4$ASPE

Thompson Peter A. purchased $15.0M of ASPE (indirect holdings)

Thompson Peter A. purchased 1,000,000 indirectly-held shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($15.00M total) on 2026-11-02.

Original reporting

SEC EDGAR · Thompson Peter A.

Published Nov 4, 2026, 11:47 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 4, 2026, 11:53 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$ASPE

Bullish

medium confidence

Mentioned

$ASPE

Relevance

8/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ASPEBullishMed

Why it matters

The transaction adds $15M of demand for ASPE shares, potentially influencing short‑term price dynamics.

Market read

Direct insider purchase is a primary disclosure that can affect ASPE's stock price in the short term.

What to watch

The purchase is indirect and may not reflect immediate operational improvements.

Relevance 8/10Novelty 6/10Timing: after‑hours filing on 2026‑11‑04

Background

Form 4 filing from SEC EDGAR reporting an insider purchase.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ASPEBullishMedium confidence

Context

Director Peter Thompson bought 1,000,000 shares for $15M, increasing his stake to over 3.5 million shares.

Expected impact

likely upward pressure as the market prices in the insider buy

Evidence & confidence

A $15M open‑market purchase by a 10% owner is material for a small biotech and can attract buyer interest.

Market effects

Sector

May signal confidence in the neuroscience sector, potentially lifting peer sentiment.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact beyond niche biotech community.

Counterpoint

What could challenge this read

Insider buying could be a routine portfolio rebalancing rather than a bullish signal.

Key entities

Director / 10% Owner
Thompson Peter A.
Insider who executed the purchase.
Company
Aspen Neuroscience, Inc.
Biotech firm focused on neuroscience therapeutics.

Read at source ← All news

NOV 4

$ASPEMedAI 8/10

ORBIMED ADVISORS LLC purchased $15.0M of ASPE (indirect holdings)

ORBIMED ADVISORS LLC purchased 1,000,000 indirectly-held shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($15.00M total) on 2026-11-02. Filed jointly with OrbiMed Capital GP VII LLC (Director).

SEC EDGAR

NOV 3

$ASPEMedAI 8/10

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $18.0M of ASPE (indirect holdings)

ARCH Venture Fund X, L.P. purchased 1,200,000 indirectly-held shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($18.00M total) on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).

SEC EDGAR

NOV 3

$ASPELow

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $2.0M of ASPE

ARCH Venture Fund X, L.P. purchased 133,333 shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($2.00M total) across 2 trades on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).

SEC EDGAR

NOV 3

$ASPEMedAI 8/10

ARCH Venture Partners XIV, L.P. (BERNS PAUL L) purchased $18.0M of ASPE

ARCH Venture Partners XIV, L.P. purchased 1,200,000 shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($18.00M total) on 2026-11-02. Filed jointly with ARCH Venture Partners XIV, LLC (10% owner), ARCH Venture Fund XIV, L.P. (10% owner) and BERNS PAUL L (10% owner).

SEC EDGAR

NOV 2

$ASPEHighAI 9/10

Aspen Neuroscience, Inc. (ASPE): Amendments to Certificate of Incorporation or Bylaws; Change in Fiscal Year

Aspen Neuroscience, Inc. (ASPE) filed an SEC Form 8-K — Other Events. Item 5.03 Amendments to Certificate of Incorporation or Bylaws; Change in Fiscal Year. On November 2, 2026, in connection with the closing of the initial public offering (the “ IPO ”) of Aspen Neuroscience, Inc. (the “ Company ”), the Company’s amended and restated certificate of

SEC EDGAR 8-K

OCT 30

$ASPEMedAI 8/10

Aspen Neuroscience, Autologous Cell Therapies for Neurological Disease, Files for Nasdaq IPO

Aspen Neuroscience plans to raise $140.6M via IPO, offering 9.375M shares at $15 each. The company, developing Parkinson's disease cell therapy sasineprocel, will list on Nasdaq under ASPE. Proceeds will fund clinical trials and working capital. The company reported a $36.5M net loss for the first half of 2026.

tradingview.com

Thompson Peter A. purchased $15.0M of ASPE (indirect holdings)

The 30-second read

Why it matters

Market read

What to watch

Background

Ticker impact

Market effects

Counterpoint

Key entities

Full insider trading history

Related articles

ORBIMED ADVISORS LLC purchased $15.0M of ASPE (indirect holdings)

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $18.0M of ASPE (indirect holdings)

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $2.0M of ASPE

ARCH Venture Partners XIV, L.P. (BERNS PAUL L) purchased $18.0M of ASPE

Aspen Neuroscience, Inc. (ASPE): Amendments to Certificate of Incorporation or Bylaws; Change in Fiscal Year

Aspen Neuroscience, Autologous Cell Therapies for Neurological Disease, Files for Nasdaq IPO